VSE for Vaccine Production
At Virica Biotech, our proprietary Viral Sensitizers (VSE™) enhance vaccine manufacturing by optimizing virus production and significantly increasing vaccine yield. VSEs transiently modulate innate cellular defenses, enabling more efficient and scalable vaccine production. Whether you’re scaling early-stage development or ramping up for global distribution, our VSEs offer a plug-and-play solution for high-yield vaccine manufacturing to rapidly meet global immunization demands.
VSEs for Vaccine Production
Increase Vaccine Manufacturing
Rapidly enhance cellular productivity and reduce production complexity across diverse vaccine platforms. By optimizing upstream processes, our cutting-edge cell enhancers help vaccine researchers and manufacturers achieve higher yields, greater product consistency, and shorter development timelines.
Benefits
- Up to 10x increase in viral yields
- Proven efficacy across human and animal health vaccine applications
- Compatible with multiple cell lines and virus types
- Works across both cell-based and egg-based production platforms
- Accelerates vaccine manufacturing
- Reduces production costs
- Improves scalability
Addition of VSE™ during Vero-cell based production of various strains of Influenza showed enhancements in titer between 1.8-5.6 fold.
Addition of VSE™ in ovo demonstrates 6-fold enhancement of Influenza (H1N1) infectious titer (n=6 independent experiments), with no significant impact on embryo weight.
Ready to Accelerate Vaccine Production?
Whether you’re working in human health, animal health, or both, our VSE technology supports fast, reliable, and scalable vaccine development at every stage.
Start a conversation with our team and discover how VSEs can help you increase vaccine yield, accelerate timelines and cut manufacturing costs.